Artera.io, combining human and AI agent intelligence to fix patient communications, recently announced a $65 million growth investment and a major milestone of reaching $100 million in Contracted ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO ...

As the adoption of artificial intelligence in healthcare rapidly grows, health tech company Artera aims to stay out in front in the race to deploy AI agents. The 10-year-old company has been ...

Colorectal cancer remains a formidable challenge in American healthcare, projected to claim over 55,000 lives in 2026 1. While early-stage detection boasts a survival rate exceeding 90 percent 2, a ...

Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced U.S. Food and Drug Administration (FDA) clearance of ArteraAI Breast ...

SANTA BARBARA, Calif., May 7, 2026 /PRNewswire/ -- Artera.io, combining human and AI agent intelligence to fix the patient experience, today unveiled its AI Services Model for Specialty Care, FQHCs ...

California-based Artera, an agentic AI company that aims to help healthcare providers with patient communication, announced today the appointment of Damon Lanphear as its new chief technology officer.

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...